Guest Commentary

Guest Commentary

The Present and Future Multiple Myeloma Landscape

The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...

Current Issue

March 2018, Volume 4, Issue 4

This issue features a debate over whether CPX-351 can be used with other therapies in AML, a look at contract research organizations, and more.